FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine
Links shared publicly online about this topic.
- 1,357total visits
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine
View full resource at news-medical.net
Tags: Meningitis, Pneumococcal Vaccine, Protein, Drug, FDA, Vaccine, Prevnar, Pfizer
Most Recently Shared on February 25, 2010 at 10:40 am By:
Meningitis News: FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine: Pfizer Inc. announced today that... http://bit.ly/bOQF86
Also Shared By:
FDA Greenlights Pneumonia Vaccine
medicalnewstoday.com — “The FDA has approved Prevnar 13, for use on people over 50. Prevnar 13 is a pneumococcal 13-valent conjugate vaccine, that can prevent pneumonia and disease caused by the bacterium, Streptococ” View full resource at medicalnewstoday.com
Most Recently Shared on January 2, 2012 at 6:05 pm By:
MedicalNewsToday: FDA Greenlights Pneumonia Vaccine http://t.co/CVwo11L4 Full http://t.co/XexlS93r
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults
news-medical.net — “Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.” View full resource at news-medical.net
Most Recently Shared on December 31, 2011 at 9:55 am By:
Meningitis News: FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults: Pf... http://t.co/4eorFS2i
Kids' Pneumococcal Vaccine Elicits Response in Adults - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- The pneumococcal 13-valent conjugate vaccine (Prevnar 13) -- which is approved for infants and children younger than 6 -- was immunogenic in adults 50 and older, Pfizer announced.” View full resource at qualitypointtech.net
Most Recently Shared on May 9, 2011 at 8:45 pm By:
Kids' Pneumococcal Vaccine Elicits Response in Adults: (MedPage Today) -- The pneumococcal 13-valent conjugate va... http://bit.ly/iFoB8K
Supplemental NDA submitted for Prevnar 13 in older adults - MPR
empr.com — “Pfizer announced that it has submitted a supplemental NDA (sNDA) to the FDA to expand the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.” View full resource at empr.com
Most Recently Shared on December 23, 2010 at 6:23 pm By:
MPR News: Supplemental NDA submitted for Prevnar 13 in older adults: Pfizer announced that it has submitted a su... http://bit.ly/f9E30H
Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease
news-medical.net — “Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.” View full resource at news-medical.net
Most Recently Shared on December 23, 2010 at 10:36 am By:
Meningitis News: Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease: Pfiz... http://bit.ly/eq2rKO
Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010
pfizer.mediaroom.com — “Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older - Dec 22, 2010” View full resource at pfizer.mediaroom.com
Most Recently Shared on December 22, 2010 at 7:50 pm By:
Pfizer submits applications to FDA and EMA for use of its pneumococcal conjugate vaccine in adults 50 and older: http://bit.ly/g6Z07K
Pfizer Receives FDA Approval For Prevnar 13™ For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children
medicalnewstoday.com — “Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CR” View full resource at medicalnewstoday.com
Most Recently Shared on February 26, 2010 at 2:16 pm By:
MNT Pediatrics News Pediatrics and Health News
Pfizer Receives FDA Approval For Prevnar 13™ For The Prevention Of Invasive Pneumococcal Disease In Infants And ... http://mnt.to/3y8Z
FDA Approves Prevnar 13 Pneumococcal Disease Vaccine
drugs.com — “Prevnar 13 (pneumococcal 13-valent conjugate vaccine) is used for prophylaxis of pneumococcal disease. Includes Prevnar 13 side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on February 26, 2010 at 1:03 am By:
FDA Approves Prevnar 13 Pneumococcal Disease Vaccine - http://bit.ly/cx9k4D
FDA Approves Pneumococcal Disease Vaccine With Broader Protection
medicalnewstoday.com — “The U.S. Food and Drug Administration approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor” View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2010 at 2:55 pm By:
FDA Approves Pneumococcal Disease Vaccine With Broader Protection The U.S. Food and Drug Administration approved Prev.. http://bit.ly/adkhzF
Medical News: New Version of Pneumococcal Vaccine Gets Okay - in Product Alert, Devices and Vaccines from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a 13-valent version of the pneumococcal conjugate vaccine Prevnar for use in pediatric patients 6 months to 5 years old.” View full resource at medpagetoday.com
Most Recently Shared on February 24, 2010 at 8:42 pm By:
New Version of Pneumococcal Vaccine Gets Okay WASHINGTON (MedPage Today) -- The FDA has approved a 13-valent version .. http://bit.ly/amhGBA
FDA Approves Pneumococcal Disease Vaccine with Broader Protection
fda.gov — “The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.” View full resource at fda.gov
Most Recently Shared on February 24, 2010 at 6:31 pm By:
Len Leshin Physician, Doctor, and Pediatrician
FDA approves new #Pneumococcal Vaccine with Broader Protection for infants, toddlers http://bit.ly/9as7JB #pediatrics #Prevnar
Pfizer provides update on Prevnar 13
news-medical.net — “Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13", (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's candidate 13-valent pneumococcal conjugate vaccine.” View full resource at news-medical.net
Most Recently Shared on December 31, 2009 at 5:45 am By:
Pfizer provides update on Prevnar 13: Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) ... http://bit.ly/7DuXdf
Advertisement
News-Medical.Net
@NewsMedical
Pfizer provides update on Prevnar 13: Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) ... http://bit.ly/7DuXdf
1 year ago...